Cargando…
COVID-19 seroprevalence in Pakistan: a cross-sectional study
OBJECTIVES: This study adapted WHO’s ‘Unity Study’ protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection. DESIGN: This population-based, age-stratified cross-sectional study was conducted at the level of households (HH). PARTI...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987211/ https://www.ncbi.nlm.nih.gov/pubmed/35387815 http://dx.doi.org/10.1136/bmjopen-2021-055381 |
_version_ | 1784682690670231552 |
---|---|
author | Ahmad, Ahsan M Shahzad, Khurram Masood, Mariumn Umar, Maida Abbasi, Fahad Hafeez, Assad |
author_facet | Ahmad, Ahsan M Shahzad, Khurram Masood, Mariumn Umar, Maida Abbasi, Fahad Hafeez, Assad |
author_sort | Ahmad, Ahsan M |
collection | PubMed |
description | OBJECTIVES: This study adapted WHO’s ‘Unity Study’ protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection. DESIGN: This population-based, age-stratified cross-sectional study was conducted at the level of households (HH). PARTICIPANTS: All ages and genders were eligible for the study (exclusion criteria: contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar. PRIMARY AND SECONDARY OUTCOME MEASURES: Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured) due to operational reasons and time constraints: - Primary indicators: Seroprevalence (population and age specific). Secondary indicators: Population groups most at risk for SARS-CoV-2-infection. RESULTS: Overall seroprevalence of SARS-CoV-2 antibodies was 7.1%. 6.3% of individuals were IgG positive while IgM positivity was 1.9%. Seroprevalence in districts ranged from 0% (Ghotki) to 17% (Gilgit). The seroprevalence among different age groups ranged from 3.9% (0–9 years) to 10.1% (40–59 years). There were no significant differences in the overall seroprevalence for males and females. A history of contact with a confirmed COVID-19 case, urban residence and mask use were key risk factors for developing SARS-CoV-2 infection. CONCLUSIONS: This survey provides useful estimates for seroprevalence in the general population and information on risk factors for developing SARS-CoV-2 infection in the country. It is premised that similar studies need to be replicated at the population level on a regular basis to monitor the disease and immunity patterns related to COVID-19. |
format | Online Article Text |
id | pubmed-8987211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-89872112022-04-07 COVID-19 seroprevalence in Pakistan: a cross-sectional study Ahmad, Ahsan M Shahzad, Khurram Masood, Mariumn Umar, Maida Abbasi, Fahad Hafeez, Assad BMJ Open Epidemiology OBJECTIVES: This study adapted WHO’s ‘Unity Study’ protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection. DESIGN: This population-based, age-stratified cross-sectional study was conducted at the level of households (HH). PARTICIPANTS: All ages and genders were eligible for the study (exclusion criteria: contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar. PRIMARY AND SECONDARY OUTCOME MEASURES: Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured) due to operational reasons and time constraints: - Primary indicators: Seroprevalence (population and age specific). Secondary indicators: Population groups most at risk for SARS-CoV-2-infection. RESULTS: Overall seroprevalence of SARS-CoV-2 antibodies was 7.1%. 6.3% of individuals were IgG positive while IgM positivity was 1.9%. Seroprevalence in districts ranged from 0% (Ghotki) to 17% (Gilgit). The seroprevalence among different age groups ranged from 3.9% (0–9 years) to 10.1% (40–59 years). There were no significant differences in the overall seroprevalence for males and females. A history of contact with a confirmed COVID-19 case, urban residence and mask use were key risk factors for developing SARS-CoV-2 infection. CONCLUSIONS: This survey provides useful estimates for seroprevalence in the general population and information on risk factors for developing SARS-CoV-2 infection in the country. It is premised that similar studies need to be replicated at the population level on a regular basis to monitor the disease and immunity patterns related to COVID-19. BMJ Publishing Group 2022-04-06 /pmc/articles/PMC8987211/ /pubmed/35387815 http://dx.doi.org/10.1136/bmjopen-2021-055381 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Epidemiology Ahmad, Ahsan M Shahzad, Khurram Masood, Mariumn Umar, Maida Abbasi, Fahad Hafeez, Assad COVID-19 seroprevalence in Pakistan: a cross-sectional study |
title | COVID-19 seroprevalence in Pakistan: a cross-sectional study |
title_full | COVID-19 seroprevalence in Pakistan: a cross-sectional study |
title_fullStr | COVID-19 seroprevalence in Pakistan: a cross-sectional study |
title_full_unstemmed | COVID-19 seroprevalence in Pakistan: a cross-sectional study |
title_short | COVID-19 seroprevalence in Pakistan: a cross-sectional study |
title_sort | covid-19 seroprevalence in pakistan: a cross-sectional study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987211/ https://www.ncbi.nlm.nih.gov/pubmed/35387815 http://dx.doi.org/10.1136/bmjopen-2021-055381 |
work_keys_str_mv | AT ahmadahsanm covid19seroprevalenceinpakistanacrosssectionalstudy AT shahzadkhurram covid19seroprevalenceinpakistanacrosssectionalstudy AT masoodmariumn covid19seroprevalenceinpakistanacrosssectionalstudy AT umarmaida covid19seroprevalenceinpakistanacrosssectionalstudy AT abbasifahad covid19seroprevalenceinpakistanacrosssectionalstudy AT hafeezassad covid19seroprevalenceinpakistanacrosssectionalstudy |